Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

@article{Arias2009AntibioticresistantBI,
  title={Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.},
  author={C{\'e}sar A. Arias and Barbara E. Murray},
  journal={The New England journal of medicine},
  year={2009},
  volume={360 5},
  pages={
          439-43
        }
}
  • C. Arias, B. Murray
  • Published 10 December 2009
  • Medicine
  • The New England journal of medicine
Drs. Cesar Arias and Barbara Murray write that we have arrived at a point as frightening as the preantibiotic era: for patients infected with multidrug-resistant bacteria, there is no magic bullet. 

Topics from this paper

Future Trends in Antimicrobial Use
TLDR
All medical practitioners must be aware of the implications of drug resistance when prescribing therapy, as it is becoming very difficult to eradicate infections caused by these antibiotic-resistant pathogens.
Current resistance issues in antimicrobial therapy
TLDR
The human gut contains 1013 - 1014 bacteria that are exposed to selection pressure whenever antibiotics are administered, which is one of the reasons why antimicrobial therapy prescribed for the treatment of respiratory tract infection should aim to eradicate pathogenic bacteria from the site of infection and from the nasopharynx.
Antibiotic-resistant bugs in the 21st century: A public health challenge
Antimicrobial resistance, which has been reported against almost every antibiotic discovered, is one of the most urgent public health problems, threatening to undermine the effectiveness of
Resistance is futile: the bacteriocin model for addressing the antibiotic resistance challenge.
TLDR
A new paradigm in antibiotic discovery and development is proposed, one that applies ecological and evolutionary theory to design antimicrobial drugs that are more difficult and/or more costly to resist.
Bacteriophage therapy against staphylococci.
TLDR
This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases and validate the use of bacter iophages for therapy and prophylaxis against drug-resistant stAPHylococci.
New synthetic antibiotics for the treatment of Enterococcus and Campylobacter infection.
TLDR
This review focuses on antibiotic resistance mechanisms of Enterococcus and Campylobacter, and new antibacterial agents against Enterococcin and Campolobacter through de novo or semi- synthesis in the period from 2003 until mid- 2013.
Antibacterial resistance: is there a way out of the woods?
  • A. Marra
  • Medicine, Engineering
    Future microbiology
  • 2011
TLDR
The Infectious Diseases Society of America has taken on this challenge and issued a set of proposals aimed at increasing awareness and reversing the course of rising antibiotic resistance, which could result in significant increases in mortality due to infections and a concomitant decrease in life span for the populations of even the wealthiest countries.
Introduction to antibiotic resistance.
TLDR
The absolute number of new antibiotics licensed has declined especially for Gram-negative multidrug-resistant pathogens, and the reasons for this failure are presented here: market issues, big pharma changes, regulatory constraints, difficulties in finding drugable targets and suitable compounds worthy of full development.
An outbreak of New Delhi metallo-β-lactamase-1 (NDM-1) producing Enterobacteriaceae in a South African hospital: a case-control study
A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, South Africa in partial fulfilment of the requirements for the Masters in Medicine in the branch of
Antibiotics: a new hope.
  • G. Wright
  • Biology, Medicine
    Chemistry & biology
  • 2012
Antibiotic resistance is one of the most significant challenges to the health care sector in the 21st century. A myriad of resistance mechanisms have emerged over the past decades and are widely
...
1
2
3
4
5
...

References

SHOWING 1-5 OF 5 REFERENCES
Emergence and management of drug-resistant enterococcal infections
TLDR
The optimal therapy for these infections is not well established and clinical data are usually limited to case reports with conflicting results, therefore, treatment decisions may have to be based on animal models and sporadic experiences.
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.
TLDR
More rapid diagnostic testing of ESBL-producing bacteria and the possible modification of guidelines for community-onset bacteraemia associated with UTIs are required.
Daptomycin Treatment Failure for Vancomycin-Resistant Enterococcus faecium Infective Endocarditis: Impact of Protein Binding?
I. Naranjo CA.Busto Ll.SellersEM.et al.A methodforestimating theprobability ofadverse drug reactions. Clin Phannacol Ther 1981 ;30:239-45. 2. Oncken C.Gonzales D. Nides M.et al. Efficacy andsafety of
Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus
TLDR
The most striking feature of the USA300 genome is the horizontal acquisition of a novel mobile genetic element that encodes an arginine deiminase pathway and an oligopeptide permease system that could contribute to growth and survival of USA300.
Extended - spec - 5 . trum β - lactamase - producing Enterobacteriaceae : an emerging public - health concern
  • Lancet Infect Dis
  • 2008